Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry

8Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years. © 2014 Matteo Filippini,et al.

Cite

CITATION STYLE

APA

Filippini, M., Bazzani, C., Atzeni, F., Sarzi Puttini, P., Marchesoni, A., Favalli, E. G., … Gorla, R. (2014). Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: Long-term real-life data from the Lorhen registry. BioMed Research International, 2014. https://doi.org/10.1155/2014/416892

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free